Cargando…

Cabozantinib for progressive metastatic medullary thyroid cancer: a review

Medullary thyroid cancer is uncommon and patients typically present with advanced disease. Treatment options for patients with progressive, metastatic medullary thyroid cancer had been limited until recently. Tyrosine kinase inhibitors have garnered increasing interest in this subset of patients. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colombo, Joshua R, Wein, Richard O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043815/ https://www.ncbi.nlm.nih.gov/pubmed/24920914 http://dx.doi.org/10.2147/TCRM.S46041

Ejemplares similares

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature
por: Kapur, Sakshi, et al.
Publicado: (2014)

Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer
por: Hart, Christopher D, et al.
Publicado: (2013)

Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension
por: Milling, Rikke Vilsbøll, et al.
Publicado: (2018)

Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
por: Højer Wang, Linnea, et al.
Publicado: (2023)

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma
por: Schlumberger, M, et al.
Publicado: (2017)

A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer
por: Capdevila, Jaume, et al.
Publicado: (2022)

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
por: Degrauwe, Nils, et al.
Publicado: (2012)

Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model
por: Carra, Silvia, et al.
Publicado: (2021)

The treatment landscape in thyroid cancer: a focus on cabozantinib
por: Weitzman, Steven P, et al.
Publicado: (2015)

Metastatic medullary thyroid carcinoma: a new way forward
por: Angelousi, Anna, et al.
Publicado: (2022)

Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer
por: Kraeber–Bodéré, F., et al.
Publicado: (2009)

Clinical Utility of Cabozantinib in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Carcinoma: Patient Selection and Reported Outcomes
por: Roof, Logan, et al.
Publicado: (2023)

Diagnosis of medullary thyroid cancer
por: Marchisotta, Stefania, et al.
Publicado: (2009)

Molecular and Other Novel Advances in Treatment of Metastatic Epithelial and Medullary Thyroid Cancers
por: Tai, David, et al.
Publicado: (2010)

Acute Liver Failure Secondary to Metastatic Medullary Thyroid Cancer
por: Gorospe, Emmanuel C., et al.
Publicado: (2011)

Metastatic papillary thyroid cancer to cerebellum with incidental medullary microcarcinoma
por: Wang, Mawson, et al.
Publicado: (2022)

Treatment of advanced medullary thyroid cancer
por: Smit, Johannes
Publicado: (2013)

An Introduction to Managing Medullary Thyroid Cancer
por: de Groot, Jan Willem, et al.
Publicado: (2006)

Medullary Thyroid Cancer: Updates and Challenges
por: Gild, Matti L, et al.
Publicado: (2023)

Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
por: Vecchio, Sharon J. Del, et al.
Publicado: (2018)

Management of medullary carcinoma of the thyroid: a review
por: Jayasinghe, Ravindri, et al.
Publicado: (2022)

Familial non-medullary thyroid cancer: a critical review
por: Capezzone, M., et al.
Publicado: (2020)

Metastatic medullary thyroid carcinoma: A case report
por: Niafar, Mitra, et al.
Publicado: (2011)

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential
por: Bersanelli, Melissa, et al.
Publicado: (2017)

Medullary Thyroid Cancer – Feature Review and Update on Systemic Treatment
por: Dabelić, Nina, et al.
Publicado: (2020)

Genetic and Epigenetic of Medullary Thyroid Cancer
por: Khatami, Fatemeh, et al.
Publicado: (2018)

Medullary Thyroid Carcinoma Presenting as Metastatic Disease to the Breast
por: Kanteti, Archana P., et al.
Publicado: (2020)

Medullary thyroid carcinoma (MTC): unusual metastatic sites
por: Kazakou, Paraskevi, et al.
Publicado: (2021)

Development of cabozantinib for the treatment of prostate cancer
por: Vaishampayan, Ulka N
Publicado: (2014)

Targeted Treatment of Differentiated and Medullary Thyroid Cancer
por: Bales, Shannon R., et al.
Publicado: (2011)

SAT479 A Case of Thyroiditis Cause by Cabozantinib
por: Bulchandani, Sheetal, et al.
Publicado: (2023)

Metastatic Lymph Node Ratio for Predicting Recurrence in Medullary Thyroid Cancer
por: Kim, Jinyoung, et al.
Publicado: (2021)

Role of vandetanib in the management of medullary thyroid cancer
por: Brassard, Maryse, et al.
Publicado: (2012)

Advanced medullary thyroid cancer: pathophysiology and management
por: Ferreira, Carla Vaz, et al.
Publicado: (2013)

How I treat medullary thyroid cancer
por: Kiesewetter, B., et al.
Publicado: (2021)

Medullary carcinoma of the thyroid metastatic to the breast: a case report and literature review
por: Martins, Sebastião Nunes, et al.
Publicado: (2014)

Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
por: Krens, Stefanie D., et al.
Publicado: (2022)

Genetic susceptibility to hereditary non-medullary thyroid cancer
por: Kamani, Tina, et al.
Publicado: (2022)

Targeted Therapy for Medullary Thyroid Cancer: A Review
por: Priya, S. R., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_uuk1gsun78ta43fpekr290h14j